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Abstract Monoclonal antibody (mAb) technology has revolutionized treatment options for T
cell mediated diseases. However, a safe, clinically available anti-T cell antibody (ab) remains
elusive. Experience with anti-T cell agents and their propensity for causing immune-mediated
toxicities have hampered the development of anti-T cell mAb's. Furthermore, misunderstanding
regarding mechanism(s) of action of particular antibodies can influence development and
clinical prescription habits. For example, the anti-CD3 Ab OKT3 is consistently described as a
depleting Ab even though original studies showed the mechanism to be non-lytic. Future anti-T
cell mAbs are likely to be non-depletional and focused on the expansion of regulatory T cells.
This review discusses how the properties of Abs can be exploited for manipulating pathological T
cell responses in the clinic.
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The immunopathologic mechanisms driving autoimmune dis-
eases, such as multiple sclerosis (MS) and type 1 diabetes (T1D),
as well as allograft rejection are similar in that immunopathol-
ogy is mediated by antigen-specific T cells. In most animal
models of autoimmunity (uveitis, myocarditis, experimental
autoimmune encephalitis (EAE), T1D, collagen induced arthritis
(CIA) [1–5], disease development is significantly delayed or
prevented by depleting or altering the function of autoreactive
T cells. A number of therapies capable of modulating T cells
have been tested experimentally in rodents and human clinical
studies. Table 1 outlines clinically applied T cell targeting
therapeutics, and associated mechanisms and observed side
effects. These include (a) polyclonal Abs derived from horses or
rabbits against thymocyte antigens (rabbit/equine anti-
thymocyte globulin – ATG) [6]; (b) Abs and fusion proteins
capable of antagonizing co-stimulation, including abatacept
and Belatacept [7–11]; (c) mAb against the leukocyte antigen
CD52 (alemtuzumab) [12,13]; (d) as well as Ab therapies
directed against proteins, such as α4β1 integrin (VLA-4),
which are important for T cell trafficking [14]. Unfortunately,
most of these therapies not only impact T cells but target
various subsets of leukocytes resulting in broad immune
suppression and increased risk for opportunistic infections and
malignancies [15]. In addition, some therapies, including
co-stimulation blockade, may not provide sufficient modulation
required to inhibit strong immune reactions, such as acute
allograft rejection. Next generation anti-T cell Abs will need
enhanced specificity, affecting only disease relevant T cells to
minimize unwanted complications. Ideal candidatesmay induce
inactivation of T cells through non-lytic mechanism(s), promot-
ing anergy, apoptosis and/or regulatory T cell expansion
without triggering cytokine release syndrome or serum sickness
associated with T cell activation and cellular depletion [16].
Here we provide a summary of potential anti-T cell mAbs
and their associated functions with the aim of informing
clinicians and assisting in the future development of safer
and more specific T cell inactivating therapeutics.
2. Primary T cell targets
Due to limited efficacy and adverse effects associated with
anti-CD3 Abs, cache with TCR targeting has waned in recentyears. Notwithstanding, the TCR complex remains an
attractive target since virtually all T cells express a TCR,
and inhibiting TCR signaling effectively blocks activation and
expansion of T cells. Notably, recent reports suggest that
targeting other components of the TCR (Table 1), with
anti-αβTCRAb for example, may overcome the limitations
associated with anti-CD3Ab [16,17]. The TCR is a multimeric
complex consisting of heterodimer αβ or γδ chains associ-
ated with CD3 complex proteins [18]. Signaling through the
αβTCR occurs after the formation of a supra-molecular
activation cluster (SMAC) on the T cell. The αβ and γδ TCR
chains lack intracellular signaling domains, and therefore
are dependent on the CD3 complex to initiate downstream
signaling events [19] In addition to these proteins, the
co-receptors (CD4 or CD8) [20,21] and CD2 [22] also play
important roles in SMAC stabilization and TCR signal
potentiation under normal physiological conditions.
While many TCR-specific mAbs function through non-
depleting mechanisms, a variety of depleting Abs are used
clinically to treat T cell pathologies (Table 1). These therapies
include polyclonal cocktails (e.g. ATG) as well as Abs to
antigens expressed bymost cellular components of the immune
system, with anti-CD52 (e.g. alemtuzumab) being the primary
example. In both cases these Abs function through depleting
mechanisms and are associated with long-term immune
suppression. Even though alemtuzumab is expected to gain
approval for the treatment of MS in 2013, a move away from
such non-specific broad acting therapeutics is desirable.2.1. TCR and accessory molecules
The most specific regulatory body approved anti-T cell agent
was OKT3 (muronomab) [23]. OKT3 is no longer available
potentially due to its propensity to induce intracellular tyrosine
activation motif (ITAM) mediated cytokine release syndrome as
well as other life threatening events. Alterations to the Fc
portion of anti-CD3 Abs were engineered in an attempt to
increase the safety of OKT3 [24,25], however, while reduced
compared with OKT3, these Abs still induced cytokine release
and were associated with narrow therapeutic indices [26–29].
Arguably this is to be expected, considering the primary
physiological role of CD3 in T cell activation and the fact that
anti-CD3Ab or variants thereof appear to target a similar
epitope expressed within the CD3ε chain [30].
Table 1 T cell targeting monoclonal antibodies with human experience.
Target/antibody Cellular specificity Functional/mechanism(s) Safety issues Reference(s)
Anti-CD3 mAbs
Teplizumab
Humanized
IgG1
αβ T cells
γδ T cells
Non-depletional; T cell
expressing CD3 evident within
48 h post last dose.
• Anergy,
• TCR coating/modulation
• IL10 producing Treg induction
Cytokine release syndrome,
lymphopenia, neutropenia,
anemia,thrombocytopenia,
rash and pruritis, anti-drug
antibody
[26,99,111–114]
Visilizumab
Humanized
IgG2
αβ T cells
γδ T cells
Non-depletional; circulating CD3
T cells median recovery is 15 days.
• Anergy,
• TCR shedding/modulation
• Apoptosis (via Caspase 3 & 8)
Cytokine release syndrome
induced liver injury & other
symptoms (chills, pyrexia,
etc.), EBV reactivation,
ADR1
[115,116]
Novimmune CD3 αβ T cells
γδ T cells
Unknown TNF release has been
described
Otelixizumab
Chimeric IgG1
αβ T cells
γδ T cells
Non-depletional; circulating CD3
T cells median recovery is 14 days.
• TCR shedding/modulation
Cytokine release syndrome,
EBV reactivation, rash, ADR
[28,72,98]
Muromonab
Murine IgG2a
αβ T cells
γδ T cells
Non-depletional; T cell expressing
CD3 evident within 48 h post last
dose.
• TCR shedding/modulation
• Activation induced death
Cytokine release syndrome,
significant anti-drug
antibody
Product insert
[74,113,117,118]
Anti-αβ TCR mAbs
T10B9/Medi-500
Murine IgM
αβ T cells Non-depletional; T cell expressing
CD3 evident within 48 h post last
dose.
• TCR shedding/modulation
• Apoptosis induction
Cytokine release syndrome
(albeit less than observed
with OKT3), ADR
[32,119,120]
BMA-031
Murine IgG2b
αβ T cells Non-depletional; T cell expressing
CD3 evident within 14 days post
last dose.
• TCR shedding/modulation
Cytokine release syndrome
(albeit less than observed
with OKT3), ADR, fever,
chills, myalgia
[121]
TOL101
Murine IgM
αβ T cells Non-depletional; T cell expressing
CD3 evident within 48 h post last
dose.
• TCR shedding/modulation
• Regulatory T cell induction
Rash, no other drug related
AE's observed in P2 renal
transplant study
DRG
unpublished
observations
Anti-CD4 mAbs
Zanolimumab αβ T cells
γδ T cells
Dendritic cells
Partial depletion by ADCC
• TCR signal inhibition
• Selective reduction in
effector/memory populations
Pruritis, flu-like
symptoms
[122,123]
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Table 1 (continued)
Target/antibody Cellular specificity Functional/mechanism(s) Safety issues Reference(s)
BF5 αβ T cells
γδ T cells
Dendritic cells
Non-depletional; 67% of
pre-treatment CD4 levels
present at 30 days.
• Reduction in inflammatory
cytokine secretion
Edema, skin lesions [124]
Anti-CD2 mAbs
BTI-322
(Rat IgG2b)
αβ T cells
γδ T cells
NK cells
Partial depletion, recovery by
day 30
• ADCC
• CD2 shedding/modulation
Cytokine release, ADR [125–127]
Anti-CD25 mAbs
Basiliximab αβ T cells
γδ T cells
NK cells
Non-depletional
• Block IL2 dependent T cell
expansion (anti-proliferative)
Gastrointestinal, fever,
rash
Product insert
Anti-CD52 mAbs
Alemtuzumab N80 targets including:
αβ T cells
γδ T cells
NK cells
Dendritic cells
Monocytes
B cells
Granulocytes
Thrombocytes
Others
Depletion of most leukocyte
subsets. Variable recovery, up
to 3 years for leukocyte
compartment to recover.
• CDC, ADCC
• Subset of memory
T cell resistant to treatment
Cytokine release syndrome,
ADR, secondary
autoimmunity infection and
malignancy
Product insert;
[13,102,103,128,129]
Anti-thymocyte globulins (polyclonal Abs)
Rabbit thymocyte
globulin (ATG)
N80 targets including:
αβ T cells
γδ T cells
NK cells
Dendritic cells
Monocytes B cells
Granulocytes
Thrombocytes
Others
Depletion of most leukocyte
subsets. Variable recovery,
up to 6 months for leukocyte
compartment to recover.
• CDC
• ADCC
Infusion reactions, ADR,
serum sickness,
thrombocytopenia,
infections and malignancy
Product insert
139Development of T cell specific monoclonal antibodiesIn the late 80s and 90s a number of anti-αβTCR Abs
were tested in an acute transplant rejection setting [31–34].
At this time, an emphasis on humanized Ab development,
the emergence of anti-IL2 receptor Abs (basiliximab and
daclizumab) and thymocyte globulins (ATG, ATGAM and
fresinius ATG) and humanized anti-CD3Ab resulted in a
reduced emphasis on anti-αβTCRAb programs. The subse-
quent failure of anti-CD3Ab in autoimmunity and new efforts
focused on understanding αβTCR signaling have seen the
reemergence anti-αβTCR Abs, with the compound TOL101
entering phase 3 renal transplant studies in 2013 [16,17].Unlike CD3, which is expressed on all T cells, the αβTCR is
restricted to T cells that recognize classical human-leukocyte
antigens (HLA). This increased specificity results in reduced
immune suppression, preserving γδ T cells for example, which
in rodents and humans has been associated with less
opportunistic infections and an increased ability to combat
severe infections [35].
Successful TCR signal initiation requires the delivery of
the lymphocyte-specific protein tyrosine kinase (Lck) by the
CD4 and CD8 co-receptor molecules [20,21]. In general T
cells express either CD4 or CD8, making these molecules
140 A. Martin et al.attractive targets for Ab therapy. Targeting CD4 with both
non-depletional and depletional Abs has been shown to be
effective in animal models of autoimmunity including in the
prevention of autoimmunity in EAE, experimental autoimmune
thyroiditis (EAT), T1D, CIA, and systemic lupus erythematosus
(SLE) [36–40]. Targeting CD8 on the other hand, has been met
with less success, with anti-CD8Ab in NOD mice capable of
preventing T1D onset only if administered before disease has
become established [41]. Clinically there is limited experience
with either CD4 or CD8 targeting Abs (Table 1).
CD2 is another protein that is central to the formation of
the SMAC, functioning to stabilize the TCR/MHC interaction
through its binding to APC-expressed LFA3, and to transduce
a required co-stimulatory signal [42]. Anti-CD2Ab treatment
has been shown to prevent the onset of adjuvant-induced
arthritis, EAE, and T1D in rodent studies [43–45]. Clinically,
alefacept, an anti-CD2 fusion protein that is approved for use in
moderate to severe plaque forming psoriasis. However, studies
in transplantation were considered to be a failure. Potentially
suggesting that different T cell targets may be better equipped
for some disease indication than others.3. Effector functions of antibodies
3.1. Depleting functions of monoclonal antibodies
Historically, mAb-mediated T cell inhibition has been described
to be the result of T cell depletion. This occurs when an anti-T
cell Ab bound to its surface antigen, interacts with Fc receptors
to induce killing (Ab-dependent cell-mediated cytotoxicity
(ADCC)), or activates complement proteins to mediate lysis
(complement-dependent cytotoxicity (CDC)). Different Ab
isotypes direct these processes with differential efficiencies.
Species specificity also determines the relative contributions of
each mechanism to T cell depletion. In the clinical setting the
polyclonal thymocyte globulin cocktails and alemtuzumab are
known to have strong depleting functions.
3.1.1. Antibody-dependent cell mediated cytotoxicity
ADCC is a mechanism of cell killing through which Abs bound
to surface antigens on T cells activate adjacent NK cells,
neutrophils, macrophages, or eosinophils via Fc recep-
tors. Killing occurs via apoptosis induction by perforin and
granzymes. In the mouse, immunoglobulins direct ADCC
against target cells to varying degrees, with murine IgG1
and IgG2a being the most efficient and IgG2b, IgG3, and
IgM displaying very low ADCC [46,47]. The degree of
killing can also vary in the presence of different ADCC
effector cells (i.e. macrophages versus NK cells). This is
likely linked to the expression of different Fc receptors,
which exhibit varying affinities to the immunoglobulin
subclasses [48]. It is important to note that a murine
immunoglobulin isotype may direct ADCC efficiently in
the presence of murine effector cells, but fail to do so in
the presence of human effector cells.
Based on preclinical and clinical studies, alemtuzumab is
arguably the most potent T cell depleting agent that functions,
to some degree, through ADCC induction. Unfortunately,
alemtuzumab-mediated ADCC is thought to be a primary
mechanism through which acute cytokine release syndromeand other acute side effects including fever, rash and malaise
are triggered [49,50]. Interestingly, it has been shown in vitro
that both isotype and the glycosylation pattern of alemtuzumab
is critical for this function. Only the IgG2b isotype has been
shown to have strong ADCC activity [51]. ADCC for other T
cell-specific Abs remains poorly defined. Thymocyte globulin
has recently been shown in mice and with human cells in vitro,
to function through macrophage mediated ADCC [52,53]. ADCC
activity has also been described in vitro for anti-CD3, anti-CD2
and anti-αβ TCR Abs [54].
3.1.2. Complement-dependent cytotoxicity
The complement cascade is a prominent mammalian defense
mechanism against microbial pathogens. In the classic pathway
of complement activation, immunoglobulins bound to their
respective cell-surface antigens act as a scaffold for the
binding of the complement protein C1q, which subsequently
recruits and activates the necessary enzymes for the formation
of the membrane attack complex, thereby directing lysis of
the pathogen [55]. While this process is important for the
elimination of microbial pathogens, complement can also lyse
Ab-bound host cells. Several T cell surface molecules have
been targeted by mAb therapy with the aim of depleting all T
cells, or select subsets of T cells for the prevention and/or
reversal of autoimmunity in animals. This strategy was found to
be highly dependent on several factors: the isotype of themAb,
the species in which the mAb was raised and used, and the
density of the cell-surface antigen expressed by T cells. Care
should therefore be exercised when characterizing Abs as
“poor complement fixers” or “poorly lytic” as this is highly
dependent on species-specific factors: appropriate pre-clinical
experiments should be conducted using relevant cell popula-
tions and appropriate sources of complement. Illustrative
examples of the necessity for such precautions can be found
in studies of rodent T cell depletion studies. Among rodent IgG
isotypes, there is some variability. Using anti-CD4 clone GK1.5
variable regions cloned onto mouse heavy chain constant
regions, a series of studies determined that IgM N IgG2a =
IgG2b N IgG1 N IgG3 where IgG1 was intermediately effective
at T cell depletion while IgG3 was non-depleting in mice
[56–59]. A similar scenario exists for rat immunoglobulins used
in the context of rat complement: IgM is more efficient at
directing cell lysis than the IgG subclasses while IgG2c (IgG3) is
poorly lytic [60,61]. Both rat and mouse immunoglobulins
exhibit variable abilities to direct CDC in the presence of
species-mismatched serum. This was found to be especially
true of the IgG2a isotypes, as mouse IgG2a directs CDC poorly in
rat serum [56] and rat IgG2a directs lysis poorly in mouse,
guinea pig and human serum [60–62]. In our own experience,
robust cytolysis (using rabbit complement) of murine T cells is
directed by anti-mouse-CD4 (YTS177) and anti-mouse-CD8 Abs
(YTS105), a pair of “non-depleting” rat IgG2a Abs used in
models of murine autoimmunity (AJM and RMT unpublished
observations). Finally, the target antigen can contribute to the
efficiency of CDC-mediated depletion, as illustrated by a pair of
rat-IgG2b Abs. GK1.5, directed against murine CD4 mediates
robust complement activation and T cell depletion while
RR3-16, directed against a TCR variable region, is non-
depleting [63]. Explanations for why Abs of a similar isotype
differ in their in vivo depleting ability include the biological
function of the antigens involved, as well as the antigen density
and affinity/avidity of the mAb.
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complement proteins and Fc receptors of different species can
be a hurdle to translational research in humanized mouse
models. The performance of a promising candidate mAb in a
humanized mouse in the presence of mouse complement and
mouse and/or human Fc receptors may not accurately predict
its performance in humans. For instance, the anti-αβ TCR mAb
TOL101, binds complement in vitro but very little T cell
depletion is detected in vivo (DRG unpublished observation).
Additionally, some Abs fail to fix complement and thereforewill
not induce CDC. Indeed, this has been described for some
anti-αβ TCR Abs [64]. This is also the case for OKT3, as
humanized CD3 products display little CDC in vitro [53]. On the
other hand thymocyte globulin as well as alemtuzumab, at least
in vitro, are capable of fixing complement. In such studies the
glycolsylation pattern of alemtuzumab has been shown to be a
critical component for complement fixation, as well as ADCC,
with changes within the carbohydrate moiety impacting the
cytotoxic capability of the Ab. In fact removal of all
carbohydrate moieties results in complete abolishment of lytic
activity ([65,66]).
Clinically, an important element to be considered when
attempting to harness CDC for T cell depletion is the
availability of complement. Complement is most abundant
within the intravascular space. Abs and/or concomitant
medications (for example steroids) trigger T cell extrava-
sation into the extravascular space leading to reduced
CDC. Finally, it has recently been described that comple-
ment exhaustion may also occur, and should be considered
when Ab will be administered numerous times to deplete
T cells.
3.1.3. Activation induced cell death
Activation induced cell death (AICD), originally defined
in-vitro in T cells treated with anti-CD3Ab, is a process
colloquially referring to T cell death triggered by TCR
activation (that is signal 1) in the absence of co-stimulation
(signal 2) [67]. In the case of anti-CD3Ab induced AICD, T cell
apoptosis is the result of caspase 8 activation via death
receptors, such as those within the Tumor Necrosis Factor
(TNF) superfamily [68].
While Abs against human T cells, such as OKT3, ATG (at high
concentrations) and anti-CD52Ab induce AICD in vitro, evidence
for in vivo AICD in humans is less clear. One confounding factor is
that primary T cells express high levels of the caspase 8 homolog
FLIP, which blocks AICD [69]. In addition to the potential of
reduced susceptibility of T cells to AICD in vivo, chemical
immune suppressants commonly used as adjunctive therapies in
autoimmunity and transplantation, (e.g. tacrolimus) inhibit
AICD in vitro highlighting the importance of viewing mAb
function within the broad context of patient care.
3.2. Nondepleting functions of monoclonal antibodies
Factors associated with Ab affinity and avidity as well as the
localization of T cell populations, complement and other
accessory proteins and cells are all likely to play a role in the
depleting capacity of mAbs. In rodents, the anti-CD25 clone
PC61.5 is a non-depleting functionally inactivating Ab [70].
Clinically, OKT3 as well as αβ TCR-specific Ab fix comple-
ment in vitro but lack a depleting function based onrepopulation kinetics and the elevation of CD2+CD3−
circulating T in patients 24 h after treatment [71–74].
Instead, Ab binding appears to promote the shedding and/
or internalization of Ab-targeted surface proteins, anergy,
and Treg expansion [5,74,75].3.2.1. Protein shedding and internalization
The precise intracellular mechanisms behind capping
and protein internalization/shedding are poorly defined,
with multiple mechanisms for each process possible [76].
Ab-specific characteristics including target, avidity and
affinity are all likely to be involved [76]. Protein shedding
and internalization have different outcomes, however, cap-
ping induced by anti-T cell Ab binding plays an important role
in both. This occurs when ligand-bound Abs accumulate at one
pole of the cell [77,78]. The cytoskeletal process(es) as well as
the precise trigger that promotes either shedding or internal-
ization remain to be clarified.
Shedding is a process whereby, through proteolytic cleav-
age, extracellular domains of receptors are released from the
cell surface [79,80]. The shed protein is usually degraded by
extracellular proteases. However, shed proteins, as seen for
cytokine receptors, may act as a decoy or neutralizing agent.
Conversely, internalization is the process through which the
entire protein is translocated from the extracellular to
intracellular space. In some instances the receptor is digested
by cytosolic enzymes, however, it may also be recycled and
re-expressed.
Nondepleting T cell-specific Abs that cause shedding
and/or internalization alter expression and function of the
bound protein, and possibly proteins that are physically
associated with (or in close proximity to) the actual target.
Indeed Abs specific for the different TCR chains typically
induce shedding/internalization of the entire receptor com-
plex. With reduced functional TCR surface expression, T
cells are unable to respond to antigenic stimuli, and are
rendered functionally inactive. How long this inactivation lasts
is dependent on the anti-T cell Ab used as well as other
parallel mechanisms that alter T cell function, such as TCR
revision and/or anergy.3.2.2. T cell receptor revision
A potential outcome of reduced TCR expression is the
re-expression of TCR encoded by genes generated by post-
thymic DNA rearrangement [72,81–85]. This process is
mediated by the re-expression of RAG-1 and RAG-2 in
peripheral T cells, is referred to as receptor revision, and
provides a mechanism by which the TCR repertoire is varied
[81–84,86]. Receptor revision observations have been
limited to some in vitro studies on T cells stimulated with
anti-TCR Abs [81–86]. The consequences of TCR repertoire
revision are incompletely understood, but it is conceivable
that Abs altering the TCR repertoire may have either
beneficial or harmful effects, and should be treated with
caution. From the perspective of autoimmunity,
re-expression of non-self specific TCR is clearly beneficial,
however, revision may promote the emergence of new
self-specific TCR capable of promoting autoimmunity
[81–84,86]. While unlikely to be a result of receptor revision
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treated MS patients reiterates this point [49].3.2.3. Anergy
Anergy is a state in which T cells are rendered nonresponsive or
hyporesponsive [87]. As such the induction of anergy is a
primary tolerance strategy for the treatment of autoimmunity
and transplant rejection. There are two primary forms of
anergy, namely clonal anergy and adaptive tolerance [87].
Clonally anergic T cells undergo early activation including
several rounds of proliferation before entering a hyporesponsive
state. This anergic pathway is argued to be a primary pathway
through which anti-TCR Abs, including anti-CD3Ab induce T cell
inactivation. Both forms of anergy are reversible, with IL-2
capable of reversing clonal anergy, and the removal of antigenic
stimulation reversing adaptive tolerance. Maintenance of
long-term tolerance is more complex, in which short-term
anergy works synergistically with the expansion of antigen-
specific Treg [17,88].3.2.4. Induction of regulatory T cells
Foxp3+Treg are potent effectors that regulate CD4+ and CD8+ T
cell differentiation and function, and antigen presenting cell
activation and maturation [89]. In rodents, Foxp3+Treg have
been used to prevent allograft rejection and treat autoimmu-
nity. In humans a clear therapeutic effect of Foxp3+Treg
remains to be definitively shown, however, genetic deficiencies
resulting in the lack of Foxp3+Treg is a direct cause of a number
of autoimmune syndromes [89].
Notably, most clinically applied Abs used to target T cells
have been described to support Foxp3+Treg induction in vitro
and/or in vivo. Depleting Abs such as ATG and alemtuzumab
have been associated with increased numbers of Foxp3+Treg,
arguably a result of resistance to depletion and proliferation in
response to lymphopenia [90–92]. Studies with anti-CD3Ab,
predominately with teplizumab, have also shown that TH1 cells
are effectively suppressed through AICD and anergy. Similar to
ATG and alemtuzumab studies, Treg populations are not only
spared from being inactivated by teplizumab, but are also
increased in number. This is presumed to be the result of TGFβ
secretion in response to apoptotic cell death of effector T cells,
together culminating in the expansion of interleukin 10
producing Tregs [93,94].
While both depleting and nondepleting anti-CD3 Abs induce
Foxp3+Treg, the side effects associated with broad immune
depletion as well as large scale T cell activation remain
drawbacks for these therapies. Of interest is the potential for
next generation anti-TCR therapies, including those targeting
the αβTCR and/or CD4 and CD8 co-receptors. In the context of
TOL101 anti-αβTCR Ab, renal transplant patients were
observed to have increased Treg (CD4 + CD25 + Foxp3 +
CD127lo), in the absence of significant adverse side effects
(DRG unpublished observation). In summary, the ability to
induce Treg appears to be a common property of T cell Abs,
however, the impact in relation to disease treatment remains to
be understood, with side effects and other Ab mechanisms
making it difficult to make concise conclusions.4. Therapeutic perceptions and opportunities
To this point the focus has predominately been on functional
capabilities of mAbs and consequences. Here potential contro-
versies as well as future directions of anti-T cell mAb therapy is
discussed, including the potential for such treatments in
disorders associated with B cells.
4.1. Short course immune induction using anti-T cell
therapeutics
How T cell inactivating mAbs are employed will depend on the
disease condition being treated. The most common application
of T cell inactivating Abs is short course immune induction
therapy (SCIIT) [16,17]. SCIIT involves the infusion of mAbs to
rapidly and temporarily modulate T cell function to induce a
period of operational tolerance or T cell non-responsiveness.
Careful examination of how anti-T cell therapy fits with current
standard of care, the potential for contraindications, and safety
are all clearly important considerations. Often ignored,
mechanisms of action are important especially when combining
immune modulators in the clinic. For example, in transplanta-
tion, the combination of T cell depleting agents with the
co-stimulation inhibitor belatacept makes little sense in the
early post-transplant period, as there may not be any cells
expressing the co-stimulation target [95]. Finally, when
considering safety measures, a keen eye on perceived immuno-
genicity resulting from the infusion of a foreign protein, versus
issues associated with target activation and Ab function need to
be defined. As an example, anti-CD3Abmitogenicity may play a
role in its inhibitory ability, and reducing this may reduce
clinical potential. Here we briefly discuss some controversial
concepts and future strategies whereby anti-T cell Ab therapy
can be employed, including in diseases whereby pathology has
commonly been associated with B cells.
In the context of transplantation, SCIIT is employed to
reduce the potential for graft rejection within the first year
post transplant [16,17]. T cell inactivating agents such as
thymoglobulin, alemtuzumab and basiliximab are given for
one to six days at the time of transplantation [17]. The precise
therapy prescribed is based upon a number of factors including
patient immunologic risk factors and cost of treatment.
Despite historical evidence highlighting the efficacy of
non-depleting anti-CD3 Abs [96], broadly ablative therapies
such as thymoglobulin are often described as the most
efficacious agents currently in use. Unfortunately the broadly
depleting mechanism of action results in uneven immune
reconstitution and dose cannot be titrated once depletion
occurs. The need for safer therapies suggests that amove back
toward non-depleting agents is warranted.
Short course immune induction with anti-CD3 and anti-αβ
TCR Abs have also shown utility in both spontaneous and T cell
transfer rodent models of T1D [75,97]. These, and subsequent
experiments, showed that efficacy of anti-CD3Ab treatment in
NOD mice is in part the result of ADCC death of effector T cells
and the expansion of Treg. These data, combined with arguably
solid phase 2 human data, served as primary support for the
initiation of two large multi-center studies using humanized
anti-CD3Ab in new-onset T1D patients [26,28,98,99]. Unfortu-
nately these studies failed to meet their primary end points.
While there remains some debate surrounding the utility of the
143Development of T cell specific monoclonal antibodiesend points used in these studies, it was clear that humanized
anti-CD3Ab treatment in this T1D patient cohort merely
extended the honeymoon period with little long-term impact
on insulin requirements. In rodents, anti-CD3Ab results in
significant T cell activation and cytokine release, a process
that is reduced in humans treated with humanized anti-CD3Ab,
a potential reason for poor efficacy. It is also plausible that
significant T cell activation is required for full anti-CD3Ab
efficacy in human patients. In addition, the time of T1D clinical
diagnosis is unlikely to represent the beginning of the disease
process, but a time point whereby pathology has been ongoing
for many years. As such there may be insufficient pancreatic
islet cell mass remaining at “clinical onset” to restore insulin
homeostasis even after the autoimmune attack on the pancreas
has been abolished. An optimal treatment window has been
described in NOD mice for anti-CD3Ab treatment, with
successful treatment observed only recently after onset. On
the other hand, early studies with anti-αβTCR Abs showed
enhanced flexibility relative to anti-CD3 Abs in regard to timing
[100]. Furthermore, disease reversal by blocking IL-7R signaling,
has also been described in mice [101]. Moving forward, TCR
targeting in T1D requires further elucidation of the patient
profile and functional capacity of the islet cells that remain.
Today, combination of successful T cell inactivation with the
administration of low levels of insulin or combined with an islet
cell transplant are the only potential options that incorporate
anti-TCRAb treatment. Both scenarios require cost-benefit
analysis, as they arguably offer little advantage over careful
daily monitoring of glucose levels and insulin injections.
Interestingly, similar issues exist when developing anti-T cell
agents for use in MS patients who have experienced significant
neurological sequelae as a result of multiple autoimmune
insults. In these patients, damage to the brain is unlikely to be
reversed by simply restoring self-tolerance or restricting
pathologic T cell activity. However, in non-progressive situa-
tions, or relapsing remitting patients, SCIIT appears to be a very
viable option, with anti-TCR agents capable of reversing or
inhibiting EAE and recent alemtuzumab clinical trials showing
positive results in relapsing remitting patients [3,13,102–104].
Other considerations for T cellmAbs therapy include location
and phenotype of T cells. For instance, in rheumatoid arthritis
(RA), pathogenic T cells are found predominately in the joints
and express a memory/activated phenotype [105]. Penetration
into the synovium for mAbs is complicated, and memory T cells
have shown resistance tomany of the available T cell therapies,
including thymoglobulin and alemtuzumab [106]. In the case of
inaccessible tissues, short course induction may not be possible
if intact Abs are used. ScFv on the other hand are small enough
to penetrate the synovium and the short-acting activity is
thought to provide the correct balance between immune
suppression and safety in RA patients. With this objective in
mind, pre-clinical investigation using anti-αβ TCR specific short
chain fragment variables that induce short-term, rapidly
reversible T cell inactivation is ongoing in the Getts laboratory.4.2. T cell inactivation potential in B-cell/antibody
mediated disorders
Much focus is given to the utility of T cell inactivating products
in diseases such as transplantation and T cell autoimmunity.
However, there may be utility for T cell inactivating agents indisorders traditionally associated with B cells. Although there
has not beenmuch research into this areawhen considering that
many B cell responses, including the production of certain Abs,
are T cell dependent, further investigation is warranted
especially in the use of T cell specific Abs that may reduce or
inhibit the pathogenesis of disorders such as chronic Ab
mediated allograft rejection and systemic lupus erythematosus.
Chronic rejection is primarily thought to be the result of B
cells making anti-donor Abs, that bind to the transplant organ,
resulting in complement activation as well as other anti-
allograft immune pathways [107,108]. In the case of patients
that do not have pre-existing (i.e. pre-transplant) donor
specific Abs, chronic rejection is likely to be the result of T
cell supported B cell maturation and Ab production. Under such
a scenario, it is plausible that the best treatment for chronic
allograft rejection may need to be multi-pronged, combining T
cell antagonist anti-B cell agents as well as complement
inhibitors. As a good animal model for chronic allograft
rejection is not currently available, clinical studies combining
such strategies will be needed to examine such hypotheses.
The precise role for T cells in the etiology and progression of
SLE remains controversial. As with chronic rejection, T cells
potentially support the production of autoantibodies by B cells. In
addition, studies have clearly shown the existence of deficien-
cies in SLE patient T cells. On the one hand, T cells from SLE
patients have been shown to produce less IL-2 potentially
resulting from increased kinase IV activity [109,110]. At the
surface this may suggest that there is reduced potential for T
cells to play a role in this disorder. However, IL-2 is important
for regulatory T cell expansion, which is also dysfunctional in
SLE patients [109] and as such deficiencies in Tregs combined
with aberrant T cell activation pathwaysmay be involved.While
speculative, T cell inactivation agents capable of binding to the
TCR and inhibiting their ability to support auto-antibody
activities, while promoting Tregs may have clinical utility.
Unfortunately, very few agents with such a profile currently
exist.While anti-CD3 agents have been shown to increase Tregs,
this is the result of AICD, a process associated with cytokines,
such as TNF and type 2 interferon production, that stimulate Ab
production. On the other hand, TOL101, was recently shown to
inhibit T cell activity and expand Tregs, without causing
cytokine release syndrome (DRG unpublished observations).
Studies are clearly needed to examine the potential of a T cell
inactivating agent with this profile in SLE patients.5. Conclusion
The future of anti-T cell mAb therapy must be focused on the
development of highly specific therapies that do not trigger
potent inflammatory cascades in T cells. Furthermore, testing
candidate therapies in models that better recapitulate human
immune function is crucial. The number of functional pathways
through which Abs may function provides ample opportunity
to inactivate autoimmune responses, but also presents an array
of potential problems. While it is tempting to define Abs as
functioning through one predominant mechanism, the reality is
that depending on the target and the cellular specificity, T cell
inactivation induced by mAb therapy is likely the result of
numerous mechanisms. Understanding these mechanisms and
learning from previous experiences is an important step in the
search for safer T cell targeting agents.
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